GlcNAc De-N-acetylase Inhibitor Development Service

GlcNAc De-N-acetylase Inhibitor Development Service

GlcNAc De-N-acetylase Inhibitor Development Service at CD BioGlyco

In the glycosylphosphatidylinositol (GPI) anchoring pathway, GlcNAc de-N-acetylase is involved in the modification step of the GPI precursor, which is an enzyme involved in the glycosylation modification process. De-N-acetylase catalyzes the removal of the acetyl group in N-acetylglucosamine (GlcNAc) molecules to form N-acetyl glucosamine phosphatidylinositol (GlcNAc-PI), de-N-acetylation is a prerequisite for the mannosylation of GlcN-PI to form the subsequent GPI intermediate. At CD BioGlyco, the development of inhibitors for the biosynthetic process of GlcNAc de-N-acetylase is based on the following contents.

  • Inhibitor design and virtual screening

Based on the known structure and reaction mechanism of GlcNAc de-N-acetylase, our research team uses computational chemistry methods to conduct molecular simulations and compound structure design and predict and evaluate the interaction between compounds and enzymes in the computer. In addition, we also use high-throughput screening technology to screen compound libraries on a large scale, which quickly evaluates the inhibitory effect of a large number of compounds on enzyme activity and screens out compounds with potential GlcNAc de-N-acetylase inhibitory activity.

  • Inhibitor synthesis service

CD BioGlyco uses chemical modification, synthesis method optimization, and other means to optimize the structure of the initially screened GlcNAc de-N-acetylase inhibitor to improve its inhibitory activity and selectivity. At the same time, the subsequent inhibitor synthesis process will be guided through systematic structure-activity relationship research. We synthesize several GlcNH2-PI-based substrate analogs and test them in cells as inhibitors of GlcNAc de-N-acetylase.

  • Inhibitor analysis service

CD BioGlyco provides professional GlcNAc de-N-acetylase inhibitor analysis services.

    • We measure enzyme activity to evaluate the inhibitory effect of candidate compounds on GlcNAc de-N-acetylase, including measuring parameters such as substrate conversion rate, product production, or enzyme catalytic rate.
    • For compounds with potential inhibitory activity, we perform antienzyme kinetic studies to evaluate their interaction with GlcNAc de-N-acetylase. For example, determination of inhibition constant (Ki), reaction kinetic parameters, or other relevant parameters.
    • We verify the biological activity and effect of GlcNAc de-N-acetylase inhibitors through cell experiments or animal models, which evaluate the ability of inhibitors to inhibit enzyme activity in vivo and explore their effects on relevant signaling pathways, cellular functions, or disease models.

Fig.1 GlcNAc De-N-acetylase inhibitor development service. (CD BioGlyco)Fig.1 GlcNAc De-N-acetylase inhibitor development service. (CD BioGlyco)


Technology: Strong anion exchange HPLC analysis

Journal: Glycobiology

IF: 5.954

Published: 1999

Results: The authors studied the substrate specificity of GlcNAc-PI de-N-acetylase activity in African trypanosomes and human (HeLa) cells. The de-N-acetylase status was indirectly reflected by measuring the release of acetate from GlcNAc-PI and its analogs at different times. The results showed that the HeLa enzyme (Fig B) was pickier than the trypanosome enzyme (Fig A), which didn't act on GlcNAc-PI analogs containing 2-O-octyl-D-inositol, indicating that selective inhibition of trypanosome de-N-acetylase was possible, this enzyme should be considered as a possible therapeutic target.

Fig.2 Acetate release at different times. (Sharma, et al., 1999)Fig.2 Acetate release at different times. (Sharma, et al., 1999)


  • Disease research: The development of GlcNAc de-N-acetylase inhibitors interferes with the glycosylation modification process and regulates related signaling pathways or biological functions, thus affecting the pathogenesis of diseases. For example, inhibiting GlcNAc de-N-acetylase may help block the proliferation, metastasis, and invasion of tumor cells.
  • Immunomodulation: GlcNAc De-N-acetylase is involved in the modification and regulation of immune cell surface receptors, and has an impact on immune cell functions and immune response. Therefore, the development of GlcNAc de-N-acetylase inhibitors is used to regulate the activity and immune response of immune cells, providing new ways for the research of autoimmune diseases, inflammatory diseases, etc.
  • Glycoprotein research: Glycoproteins are a family of proteins closely related to glycosylation modifications. The development of GlcNAc de-N-acetylase inhibitors is used to study the functions and physiological effects of glycoproteins, which reveals the mechanism of glycosylation modifications in protein stability or activity.


  • CD BioGlyco has an excellent research team, who have extensive experience in GlcNAc de-N-acetylase inhibitor development and provide high-quality inhibitor development service.
  • CD BioGlyco has various technology means and tools to predict, screen, and optimize GlcNAc de-N-acetylase inhibitors, improving the flexibility and efficiency of the development process.
  • CD BioGlyco provides clients with custom GlcNAc de-N-acetylase inhibitor development programs and strategies based on their needs and goals.

CD BioGlyco provides GlcNAc de-N-acetylase inhibitor development service efficiently and flexibly, quickly adjusting and adapting to client needs to meet their requirements. Please feel free to contact us if you would like to consult about specific development content, we are your ideal partner.


  1. Sharma, D.K.; et al. Differences between the trypanosomal and human GlcNAc-PI de-N-acetylases of glycosylphosphatidylinositol membrane anchor biosynthesis. Glycobiology. 1999, 9(4): 415-422.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.